Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
LumiraDx logo — Transforming community-based healthcare through POC diagnost...

LumiraDx

Transforming community-based healthcare through POC diagnostics & making lab-comparable tests accessible to all

Founded 2014 United Kingdom London, United Kingdom 316 employees IPO Total: $825.47M Health Care, Medical Devices

General Information

Company Name LumiraDx
Founded Year 2014
Location United Kingdom London, United Kingdom
Founders / Decision Makers
Team member
Employees 316
Industries Health Care, Medical Devices
Funding Stage IPO
Business Model B2B, D2C, B2D
Revenue Model Product Sales, Service Fee, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with LumiraDx. To contact LumiraDx, visit lumiradx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does LumiraDx compare?

A PDF of LumiraDx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting LumiraDx soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About LumiraDx

LumiraDx, founded in 2014 and headquartered in the United Kingdom, is making significant strides in the healthcare sector by pioneering point-of-care (POC) diagnostics. The company's slogan, "Transforming community-based healthcare through POC diagnostics & making lab-comparable tests accessible to all," encapsulates its mission.

Recently, Roche Diagnostics acquired LumiraDx's next-generation POC Platform technology, marking a pivotal moment for the company. This acquisition underscores LumiraDx's potential to integrate globally with Roche, a leader in both pharmaceuticals and diagnostics. Roche's established expertise promises to enhance LumiraDx's innovative reach, particularly in areas such as oncology and diabetes management.

LumiraDx last secured a $14.20M grant investment in December 2022 from the Bill & Melinda Gates Foundation, highlighting investor confidence in its scalable solutions. Positioned at the intersection of Health Care and Medical Devices, LumiraDx is poised for growth in community healthcare.

Business keywords: Point-of-Care Diagnostics, Personalised Healthcare, In Vitro Diagnostics, Tissue-Based Cancer Diagnostics, Diabetes Management, Oncology, Infectious Diseases, Digital Connectivity, Clinical Integration, Population Health Management, Patient-Centered Care, Healthcare Innovation, Diagnostic-Led Care, Interoperability

Services & Products

In vitro diagnostic products
Point of care systems
Digital healthcare solutions
Assay and detection systems
Consulting and product services

Target Customers

Healthcare professionals Research institutions Hospitals and clinics Pharmacies Community outreach programs

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $14.20M 1
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
01 Dec 2022
Post IPO Convertible $56.50M -
01 Mar 2022
Spac Private Placement $115.00M 1
CA Healthcare Acquisition Corp
01 Sep 2021
Post-IPO Debt $400.00M 2
BioPharma Credit PLC
BioPharma Credit PLC, Plus Capital One
01 May 2021
Late VC $164.00M -
01 Dec 2020
Debt Financing $75.16M -
01 Oct 2019
Seed $610.00K -
01 Dec 2016

LumiraDx Alternatives & Competitors

View All Alternatives
LumiraDx vs
Mellitus, LLC
Mellitus, LLC United States

Mellitus developed a simple diagnostic test for gestational diabetes-Work continues at Harvard/MassG...

5 employees
Biotechnology, Health Care
Compare LumiraDx vs Mellitus, LLC
LumiraDx vs
i-SENS, Inc.
i-SENS, Inc. Korea South

i-SENS is a global company dedicated to improving the lives of people with diabetes and those who ca...

Series A
106 employees
Health Care, Manufacturing
Compare LumiraDx vs i-SENS, Inc.
LumiraDx vs
MIMOSA Diagnostics
MIMOSA Diagnostics Canada

Making the invisible visible

Grant
33 employees
Digital Health, Health Care
Also compare with: LumiraDx vs 1upHealth, Inc. 1upHealth, Inc. View all alternatives

FAQ About LumiraDx

Transforming community-based healthcare through POC diagnostics & making lab-comparable tests accessible to all
LumiraDx was founded in 2014.
LumiraDx is headquartered in London, United Kingdom.
LumiraDx operates in Health Care and Medical Devices. Its work centres on Point-of-Care Diagnostics, Personalised Healthcare, In Vitro Diagnostics and Tissue-Based Cancer Diagnostics. Its customers include Healthcare professionals, Research institutions and Hospitals and clinics.
LumiraDx has a B2B, D2C and B2D business model. Its revenue comes from Product Sales, Service Fee and Usage Based.
LumiraDx has approximately 316 employees.
LumiraDx has completed 7 funding rounds, raising a total of $825.47M. The latest funding stage is IPO.
LumiraDx offers: In vitro diagnostic products, Point of care systems, Digital healthcare solutions, Assay and detection systems, Consulting and product services.
Top alternatives and competitors to LumiraDx include Mellitus, LLC, i-SENS, Inc. , MIMOSA Diagnostics, 1upHealth, Inc., Labplus. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
LumiraDx and Mellitus, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for LumiraDx, https://bouncewatch.com/company/lumiradx, updated 2 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout